WDBO on MSN
Orlando Health becomes one of the first in the nation to offer new prostate cancer treatment
ORLANDO - In a press release on July 1, Orlando Health announced that is now “one of the first health systems in the nation” ...
TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...
Transurethral ablation of Gleason grade group 2 (GG2) lesions using water vapor therapy cleared the area of prostate cancer in 75% of men and 91% had no GG2 or higher-grade cancer remaining at 6 ...
Add Yahoo as a preferred source to see more of our stories on Google. Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug ...
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO ...
Francis Medical is heating up with a 510(k) clearance from the FDA for its water vapor ablation therapy aimed at cancers of the prostate, kidneys and bladder. The regulatory go-ahead for its Vanquish ...
In a trial, the ProFocal device for intermediate-risk prostate tumor ablation had an 84% treatment success rate with low morbidity. Cooled laser focal therapy ablation using a novel device (ProFocal®; ...
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
Bill Faulkner had long approached prostate cancer testing with skepticism. For almost a decade, the 73-year-old had avoided the prostate-specific antigen test because of concerns about over-diagnosis; ...
Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation therapy for cancers of the prostate, kidneys and bladder. The series C round ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results